MR Quantification of Total Liver Fat in Patients with Impaired Glucose Tolerance and Healthy Subjects

Zhi Dong1*, Yanji Luo1*, Zhongwei Zhang2, Huasong Cai1, Yanbing Li3, Tao Chan4, Ling Wu5, Ziping Li1*, Shi-Ting Feng1*

1 Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, 2 Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 3 Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 4 Medical Imaging Department, Union Hospital, Hong Kong, 5 Department of Radiology, Kiang Wu Hospital, Macao

Abstract

Objective: To explore the correlations between liver fat content and clinical index in patients with impaired glucose tolerance (IGT) and healthy subjects.

Materials and Methods: 56 subjects were enrolled and each of them underwent upper-abdominal MRI examination that involved a T1 VIBE Dixon sequence. 14 was clinically diagnosed with IGT (collectively as IGT group) while 42 showed normal glucose tolerance, (collectively as NGT group). NGT group was further divided into NGTFat (BMI≥25, 18 subjects) and NGTLean (BMI<25, 24 subjects). The total liver fat content was measured and compared with clinical findings and laboratory results in order to determine statistical correlations between these parameters. Differences among IGT, NGTFat and NGTLean groups were evaluated.

Results: For all the subjects, fat volume fractions (FVFs) ranged from 4.2% to 24.2%, positive correlations was observed with BMI, waist hip ratio(WHR), low density lipoprotein(LDL), fasting plasma insulin(FPI), homeostasis model assessment insulin resistance (HOMA-IR) and homeostasis model assessment (HOMA)[I]. FVFs of IGT group ($p=0.004$) and NGTFat group ($p=0.006$) were significantly higher than those of NGTLean group.

Conclusions: People with higher BMI, WHR and LDL levels tend to have higher liver fat content. Patients with BMI≥25 are more likely to develop IGT. Patients with higher FVF showed higher resistance to insulin, thus obtained a higher risk of developing type 2 diabetes mellitus.

Introduction

Ectopic fat deposition is commonly seen in many diseases, especially in metabolic disorders, such as obesity, insulin resistance, and other components of metabolic syndrome. It plays an important role in the development and progression of nonalcoholic fatty liver disease (NAFLD) [1–3]. It is thought to have direct positive impact on the increasing rate of obesity and NAFLD prevalence across the world [4]. According to some researchers, about 10–20% patients with NAFLD are affected by the progressive form of NAFLD, otherwise known as nonalcoholic steatohepatitis (NASH) where 20–30% of patients with NASH will develop cirrhosis and end-stage liver disease [5–7].

Liver fat content is an essential indicator for the progression of NAFLD [8]. So far, many techniques and methods have been developed for diagnosing fatty liver disease and quantifying liver fat content. This can be achieved by techniques such as liver biopsy/pathology, computed tomography (CT) scanning, ultrasound, and magnetic resonance imaging (MRI). However, all these techniques have various shortcomings. For example, the gold standard for assessing fat content in liver, biopsy/pathology, is invasive and subjective to sampling error [9–12]. CT can only be used to detect the existence of fat but not to measure the total amount of the fat content. Furthermore, the accumulative radiation exposure from repeated CT scans can be harmful which limits its role in evaluating disease progression during long term follow up. In comparison, Magnetic resonance (MR) spectroscopy has been widely-applied and can provide accurate evaluation of hepatic fat content, however, it is time consuming and evaluation only limits to part of the liver [13–15].
MR technique for quantifying fat content is based on chemical shift imaging. It is one of the most promising techniques due to its non-invasive, radiation-free and easy-to-perform characteristics [14,16]. Dixon technique is a two-point chemical shift-based fat-water separation method described by Dixon in 1984 [17]. It acquires two images with different echo times (TE) to separate the fat signals from the water signals in the same voxel (in-phase and out-of-phase). Pure fat image and water image are obtained by the following equation:

\[ W = \frac{SIP + SOP}{2} \]

\[ F = \frac{SIP - SOP}{2} \]

(W: water phase; F: fat phase; SIP: signal of in-phase; SOP: signal of out-of-phase).

With this technique, the map of fat deposition in the liver can be displayed, and the fat content across the entire liver can be measured.

Clinical and laboratory parameters such as body mass index (BMI), waist hip ratio (WHR), serum triglycerides (TG), and low density lipoprotein (LDL) levels are thought to be related to extent of fat accumulation in liver [18,19]. Accurate fat quantification of the entire liver and the investigations of the relationship between liver fat content and clinical parameters may provide information for future clinical interventions. This study aims to validate the use of Dixon technique in total liver fat content quantification, as well as to explore the correlations between liver fat content and clinical parameters in both healthy subjects and those with impaired glucose tolerance.

**Materials and Methods**

**Ethic statement**

The study was conducted in accordance with ethical guidelines for human research, the Health Insurance Portability and Accountability Act (HIPAA) and was approved by the research ethical committee of The First Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from all patients, and legal guardian if the patients were younger than 18 years old. Permission was obtained from the hospital for the publications of medical images seen in the Figures.

**Phantom validation**

We first evaluated the accuracy of the fat-quantifying technique with some fat-water phantoms. Homogeneous emulsions consisting of vegetable (peanut) oil and distilled water were prepared in 50 ml bottles, with fat volume fractions (FVF) of 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, using a magnetic stirrer hotplate heated to 50°C. Agar gel (2% by weight) and dioctyl sulfosuccinate sodium salt (15 mmol/L) were added in each bottle to stabilize the emulsions (Figure 1) [20]. All the bottles were placed in a water tank with a temperature of 37°C (mimic the temperature of normal human body).

**MR images were obtained using a 3-Tesla whole-body human MRI scanner (SIEMENS 3.0T MAGNETOM Verio). A head coil was used and T1 volumetric interpolated breath-hold examination (VIBE) Dixon sequence was applied with the following parameters: TE, 2.5 ms, 3.7 ms; TR, 5.62 ms; flip angle, 5°; receiver bandwidth, ±504.0 kHz; slice thickness, 3.0 mm. Four images of the phantoms were generated, including in-phase and out-of-phase, as well as fat and water phase images.**

**Subjects and clinical data**

Fifty-six subjects were enrolled in the study. Oral glucose tolerance test was conducted subjects were divided into either impaired glucose tolerance (IGT) group or normal glucose tolerance (NGT) group accordingly. 14 were clinically diagnosed with impaired glucose tolerance (2 males, 12 females, age range 47~58 years old, average age was 53 years old) and 42 with normal glucose tolerance (18 males, 24 females, age range 43~57 years old).
years old, average age 50 years old). Other clinical parameters and laboratory tests were also measured: BMI, WHR, body fat content (BFC), total cholesterol (CHOL), TG, LDL, fasting plasma insulin (FPI), homeostasis model assessment IR (HOMA-IR), homeostasis model assessmentβ (HOMAβ). NGT group was further divided into two groups according to BMI: NGTFat group, BMI >25 (the upper-limit in healthy people), 18 subjects (BMI: 26.6±1.4); NGTLean group, BMI <25, 24 subjects (BMI: 23.0±1.4). The BMI of all 14 patients in IGT group were higher than 25 (BMI: 28.0±2.2).
Each subject underwent an upper-abdominal MRI examination that involved an initial set of localizer images and then a T1 VIBE Dixon sequence. The imaging parameters were the same as those in the phantom study, with TE of 2.5/3.7 ms and TR of 5.47 ms. All the subjects were imaged in supine position and carefully instructed to breath hold during end inspiration to ensure consistency amongst subjects. Four images, in-phase, out-of-phase, fat-phase and water-phase, were obtained at the same time within a single breath-hold for each patient.

**MR Image post processing and analysis**

Fat volume fraction (FVF) map was generated by combining the MR images obtained during both fat-phase and water-phase of each subject. This was done by using a newly designed plug-in algorithm created under MATLAB platform (MATLAB r2011b, Figure 4. FVF maps of two typical subjects from IGT group (A) and NGTLean group (B). A: a 58 years old female who was diagnosed as IGT (BMI = 31.85), with a mean FVF of 24.23%. The fat phase and FVF map demonstrated that the deposition of fat is homogeneous. B: a 50 years old female (BMI = 23.13) with a mean FVF of 4.15%. The color of the liver in case B is much darker than that in case A, indicating a lower fat content. doi:10.1371/journal.pone.0111283.g004

**Table 1. Correlations between the liver FVF values and clinical parameters in all subjects as determined by Spearman correlation test.**

| Variables | Correlation Coefficient | P     |
|-----------|-------------------------|-------|
| BMI       | 0.595                   | 0.004 |
| BFC       | -0.024                  | 0.915 |
| WHR       | 0.432                   | 0.045 |
| CHOL      | 0.352                   | 0.108 |
| TG        | 0.689                   | 0.019 |
| LDL       | 0.455                   | 0.033 |
| FPI       | 0.886                   | 0.019 |
| HOMA-IR   | 0.886                   | 0.019 |
| HOMAβ     | 0.943                   | 0.005 |

*FVF’s have positive correlation with BMI, WHR, TG, LDL, FPI, HOMA-IR and HOMAβ, while BFC and CHOL were found to have no statistical correlation with liver fat content.

**Table 1.**

| Variables | Correlation Coefficient | P     |
|-----------|-------------------------|-------|
| BMI       | 0.595                   | 0.004 |
| BFC       | -0.024                  | 0.915 |
| WHR       | 0.432                   | 0.045 |
| CHOL      | 0.352                   | 0.108 |
| TG        | 0.689                   | 0.019 |
| LDL       | 0.455                   | 0.033 |
| FPI       | 0.886                   | 0.019 |
| HOMA-IR   | 0.886                   | 0.019 |
| HOMAβ     | 0.943                   | 0.005 |

*FVF, fat volume fraction; BMI, body mass index; BFC, body fat content; WHR, waist hip rate; CHOL, cholesterol; TG, triglyceride; LDL, low density lipoprotein; FPI, fasting plasma insulin; HOMA-IR, homeostasis model assessment insulin resistance; HOMAβ, homeostasis model assessmentβ.

doi:10.1371/journal.pone.0111283.t001
MathWorks, America), using the following equation:

\[ \text{FVF} = \frac{F}{W + F} \times 100\% \]

(FVF: fat volume fraction; F: fat volume; W: water volume).

In phantom study, two trained radiologists manually traced a round-shaped region of interest (ROI) on each bottle, and recorded the results of FVFs. The diameter of ROI is 3 cm, the size of the transverse section of the bottles. Average FVFs of each bottle were acquired.

In vivo study, two trained radiologists manually placed an irregular-shaped ROI covering the entire liver in 21 consecutive slices (max-area centered) of each patient (Figure 2). The mean FVF in the ROI of each subject was recorded.

**Statistical analysis**

FVF values were calculated using the Dixon technique and compared to true FVFs in the phantom experiment using linear correlation. In vivo study, statistical correlations between FVFs and results of clinical and laboratory tests were determined by using the Spearman’s rank correlation. The difference in FVF between three groups was evaluated using the Wilcoxon test. A p value lower than 0.05 was considered as statistically significant. All the analyses were performed in SPSS (SPSS, Version 13.0, Chicago, IL, USA).

**Results**

**Phantom study**

Figure 1 summarizes the results from the phantom study. The bottle on the lower left side is filled with pure water (fat content: 0%), and the upper right one is filled with 100% peanut oil. Others contain fat content ranging from 10% to 90%. During the fat phase image, higher fat content was associated with a higher signal intensity. The opposite was observed during the water phase image where higher fat content was associated with a lower signal intensity. FVF map demonstrated different amounts of water/fat in the emulsions ranging from 0% to 100% with changing color. A graph comparing the actual FVF against fat fraction calculated by Dixon technique also showed excellent correlation (Figure 3, \( r^2 = 0.994, p = 0.000 \)). This result indicates that Dixon technique is applicable for measuring the actual fat content of the liver.

**In vivo results**

For each subject, FVF maps were generated from the source images of both fat phase and water phase. Figure 4 shows the FVF maps of two typical subjects from IGT group (A) and NTGL Lean group (B) respectively. The darker color of the liver seen in Figure 4B indicates lower fat content in NTGL Lean group when compared to the IGT group as seen in Figure 4A. Furthermore, in both fat phase image and FVF map (Fig. 4A), the distribution of fat in liver in people with metabolic disorders tended to be homogeneous, which is different from fat accumulation caused by inflammation [21].

For all the subjects, FVFs ranged from 4.2% to 24.2%, and had positive correlation with BMI (p = 0.004), WHR (p = 0.045), TG (p = 0.019), LDL (p = 0.033), FPI (p = 0.019), HOMA-IR (p = 0.019) and HOMA\(B\) (p = 0.005) (Table 1, Spearman’s rank correlation). For IGT group, FVFs positively correlated with FPI (p = 0.019), HOMA-IR (p = 0.019), HOMA\(B\) (p = 0.005), while the FVFs of healthy groups did not show significant correlation with any of these clinical parameters.

FVFs of IGT group were significantly different from those of NTGL Lean group (p = 0.004), but no significant difference was found between IGT group and NTGFat group (p > 0.05). FVFs of NTGL Lean group were also significantly different from those of NTGFat group (p = 0.006) (Figure 5).

---

**Figure 5. Boxplots of FVF values for the IFT, NGTFat and NGTLean groups.** Significant differences was found between IGT group and NGTLean group (p = 0.004), as well as the NGTFat group and NGTLean group (p = 0.006). But there was no significant difference between IGT group and NGTFat group (p = 0.359).

doi:10.1371/journal.pone.0111283.g005
Discussion

The amount of the liver fat content is essential in monitoring the progression of NAFLD and it acts as a potential indicator of underlying metabolic disorders [22]. Unlike MR spectroscopy, Dixon technique provides us with separate fat and water phase images within a single breath-hold. Dixon technique is easier to perform than MRS; and the image analysis is also more straightforward. Liver fat content measurement and detection using Dixon technique have been reported in previous studies [23–27]. For example, D’Assignies, G. et al. have evaluated the ability of MRS, Dixon technique and diffusion-weighted MR imaging (DWI) to detect liver steatosis using histopathology as a reference [23]. They have also evaluated the correlations between fat fraction (FF) measured by MRS, Dixon technique and clinical parameters such as LDL and cholesterol concentrations, which showed consistent result with our study. However, their study mainly focuses on the sensitivity, specificity and accuracy in diagnosis of liver steatosis for three different noninvasive MR techniques, MRS, Dixon technique and DWI. In another study, Houchun H. Hu and colleagues have demonstrated a strong potential for IDEAL technique (Iterative Decomposition with Echo Asymmetry and Least squares estimation, a modified Dixon technique) as a liver fat quantification tool and a valuable method for obesity research [24]. However, in the studies mentioned above, only a small oval- or square-shaped ROI on the liver was studied, hence could not appropriately evaluate the total amount of the liver fat content.

In this study, from the separate fat and water phase images, a 3D voxel-wise fat fraction map of the entire abdomen was generated which showed the spatial pattern of ectopic fat, and mean FVF of the entire liver on the map was calculated. For each subject, 21 consecutive slices (max-area centered) of the FVF map was used to generate the liver ROI, and the mean value was recorded to stand for the FVF of this subject. Proved to be dependable by the phantom study, FVFs obtained via the Dixon technique is found to approximately equate to the actual fat content throughout the liver. The spatial information of the liver fat is also readily available (Fig. 1 and Fig. 4).

Under normal circumstance, liver plays an important role in the lipid metabolism. It is involved in free fatty acid uptake from the blood to synthesize TG, essential in the lipoprotein transportation by combining different types of lipids with lipid-carrying protein. When the efficiency of TG synthesis exceeds the transporting capacity of lipoproteins, TG and other types of lipids accumulates in the liver, resulting in fatty liver, or otherwise known as, ectopic fat deposition [1,2]. Unlike fat accumulation resulted from inflammation [21], people with metabolic disorders tend to have homogeneous fat deposition in liver, or otherwise known as, ectopic fat deposition. This study also demonstrated that liver fat content has a positive correlation with FPI, HOMA-IR and HOMAβ. That means people with higher liver fat content tend to have higher FPI, HOMA-IR and HOMAβ levels. FPI reflects the body’s sensitivity to insulin. Higher FPI is associated with lower insulin sensitivity. HOMA-IR can be calculated from FPI, which reflects insulin resistance. Thus, our results may indicate that people with high HOMA-IR levels are more resistant to insulin. Insulin resistance is recognized as a main risk factor for many metabolic disorders, and it especially increases the probability to develop type 2 diabetes [28]. In our study, FVFs of IGT group was positively correlated with FPI and HOMA-IR. In other words, IGT patients with higher FVFs are more resistant to insulin, and may have a higher risk to develop type 2 diabetes mellitus. Therefore, fat content quantification using Dixon technique has its value as a prognostic tool for IGT patients.

To summarize, this study has verified an accurate, noninvasive and easy-to-perform method based on Dixon technique to quantify the fat content across the entire liver. The significant correlations of FVF with some other clinical parameters indicate further investigations are necessary for the epidemiology and pathophysiology of NAFLD as well as other metabolism disorders.

Acknowledgments

This work was funded by National Natural Science Foundation of China (81000626), Natural Science Foundation of Guangdong Province (S2013010016004), Zhujiang Scientific and Technological New Star Foundation (2012J2200084), and the Fundamental Research Funds for the Central Universities (10ykpy11).

Author Contributions

Conceived and designed the experiments: ZL STF. Performed the experiments: HSC TC LW ZWZ. Analyzed the data: ZD YJL. Contributed reagents/materials/analysis tools: HSC TC LW. Contributed to the writing of the manuscript: ZD YJL ZL STF LW ZWZ.
References

1. Clark JM (2006) The epidemiology of nonalcoholic fatty liver disease in adults. Journal of Clinical Gastroenterology 40: S3–10.

2. Kotronen A, Pelkonen M, Hakkarainen A, Sevastianova K, Bergholm R, et al. (2009) Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137: 865–72.

3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–23.

4. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology of nonalcoholic fatty liver disease. Ann Surg 250: 691–7.

5. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994) Nonalcoholic steatohepatitis: an expanding clinical entity. Gastroenterology 107: 1101–9.

6. Angola P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–31.

7. Wieckowska A, McCullough AJ, Feldstein AE (2007) Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46: 582–9.

8. Ligabue G, Besutti G, Scaglioni R, Stentarelli C, Guaraldi G (2013) MR quantification of hepatic steatosis with MRI: the effects of accurate fat spectral angle multiecho gradient-recalled-echo imaging at 1.5 T. Eur Radiol 23: 2175–86.

9. Fernández-Salazar L, Velayos B, Aller R, Lozano F, Garrote JA (2011) Percutaneous liver biopsy: patients’ point of view. Scand J Gastroenterol 46: 727–31.

10. Bedossa P, Darge`re D, Paradis V (2003) Sampling variability of liver fibrosis in nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and therapeutics 34: 274–85.

11. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, et al. (2009) Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137: 865–72.

12. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 238: 767–73.

13. Bydder M, Yokoo T, Hamilton G, Camma` C, Pizzolanti G, et al. (2012) Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 35: 238–47.

14. Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, et al. (2009) Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250: 95–102.

15. Reeder SB, Roberts PM, Yu H, Shimakawa A, Hines CD, et al. (2009) Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 29: 1332–9.

16. Mesany S, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, et al. (2011) Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 258: 749–59.

17. Dixon WT (1984) Simple proton spectroscopic imaging. Radiology 153: 189–194.

18. Peta S, Amato MC, Di Marco V, Camma` C, Pizzolanti G, et al. (2012) Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 35: 238–47.

19. Monteiro PA, Mota J, Silveira LS, Cayres SU, Antunes BdM, et al. (2013) Morphological and metabolic determinants of nonalcoholic fatty liver disease in obese youth: a pilot study. BMC Res Notes 6: 19.

20. Bernard CP, Liney GP, Manton DJ, Turnbull LW, Langton CM (2008) Comparison of Fat Quantification Methods: A Phantom Study at 3.0T. Journal of magnetic resonance imaging 27: 192–7.

21. Kammen BF, Fahren P, Thoeni RF, Lu Y, Qasyym A, et al. (2001) Focal fatty infiltration of the liver: analysis of prevalence and CT findings in children and young adults. Am J Roentgenol 177: 1035–9.

22. Reeder SB, Cruite I, Hamilton G, Sirlin CB (2011) Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 34: 729–49.

23. D’Assignies G, Martin R, Abdesslem K, Luigi L, Miguel C, et al. (2009) Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. Eur. Radiol 19: 2033–40.

24. Hu HH, Kim HW, Nayak KS, Goran MI (2010) Comparison of fat–water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity (Silver Spring) 18: 841–7.

25. Leppör B, Ratiney H, Pilleul F, Beuf O (2013) Liver fat volume fraction quantification with fat and water T1 and T2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. Eur Radiol 23: 2175–86.

26. Yokoo T, Shirahmoteza M, Hamilton G, Wolfson T, Schroeder ME, et al. (2011) Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 258: 749–59.

27. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, et al. (2009) Nonalcoholic fatty liver disease: diagnostic and fat grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 251: 67–69.

28. Cusi K (2009) Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16: 141–9.